Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 6/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334985 | 0.93 | GPR84 (0.48) | KDM5AKDM4CAKR1B1GPR84PPARG | |
| SCHEMBL28856644 | 0.90 | MMP1 (0.42) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL28856645 | 0.90 | MMP1 (0.42) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL7781254 | 0.88 | CYP1A2 (0.44) | KDM4CALDH1A1PHF8 | |
| SCHEMBL11342740 | 0.85 | AKR1B1 (0.46) | KDM5AKDM4CAKR1B1GPR84PPARG | |
| SCHEMBL8524074 | 0.84 | ACE2 (0.42) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL10973416 | 0.84 | ACE2 (0.42) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL8523775 | 0.84 | ACE2 (0.42) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL7770709 | 0.82 | ACE2 (0.46) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL9839518 | 0.82 | ACE2 (0.46) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171165-A1 | Process for the preparation of perindopril | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-08-04 | — | — | US | claimed |
| US-20080071094-A1 | Process for the preparation of perindopril | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-03-20 | — | — | US | disclosed |
| US-7291745-B2 | Process for the preparation of perindopril | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-11-06 | — | — | US | disclosed |
| WO-2007085933-A2 | PROCESS FOR THE PREPARATION OF N-[1-(S)-ETHOXYCARBONYL-1-BUTYL]-(S)-ALANINE-DMT COMPLEX AND ITS USE IN THE PREPARATION OF PERINDOPRIL | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20060211867-A1 | Process for the preparation of perindopril | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-09-21 | — | — | US | disclosed |
| WO-2005108365-A1 | PROCESSES FOR THE PREPARATION OF ALPHA POLYMORPH OF PERINDOPRIL ERBUMINE | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250706-A1 | Processes for the preparation of alpha polymorph of perindopril erbumine | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-11-10 | — | — | US | disclosed |
| US-20050171165-A1 | Process for the preparation of perindopril | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211867-A1 | Process for the preparation of perindopril | ACE, PRSS1, CYP2S1 | KDM5A 554/4885KDM4C 823/4885AKR1B1 209/4885 |
| US-20050250706-A1 | Processes for the preparation of alpha polymorph of perindopril erbumine | REN, VKORC1, VKORC1L1 | KDM5A 3107/4885KDM4C 2847/4885AKR1B1 13/4885 |
| US-20080071094-A1 | Process for the preparation of perindopril | ACE, PRSS1, CYP2S1 | KDM5A 554/4885KDM4C 823/4885AKR1B1 209/4885 |
| US-20050171165-A1 | Process for the preparation of perindopril | SPR, QDPR, DPYD | KDM5A 435/4885KDM4C 1710/4885AKR1B1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.